PUBLISHER: Grand View Research | PRODUCT CODE: 1405759
PUBLISHER: Grand View Research | PRODUCT CODE: 1405759
The global calcium hydroxylapatite (CaHA) fillers market is expected to reach USD 1.6 billion by 2030 and it is projected to grow at a CAGR of 13.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to grow due to factors such as growing regulatory approvals for combination dermal fillers, changing aesthetic standards across developed and developing countries, favorable financial accessibility options for patients, and an increasing population of geriatric patients susceptible to facial wrinkles and volume loss.
The industry's growth is driven by the increasing adoption and development of advanced calcium hydroxylapatite (CaHA) fillers. The integration of hyaluronic acid (HA) with calcium hydroxylapatite (CaHA) to aid in patients suffering from facial volume loss aids growth. For instance, HA contributes to immediate volumizing effects, addressing fine lines and wrinkles. In addition, CaHA's collagen-stimulating properties lead to sustaining results, extending the longevity of the treatment.
An increase in strategic initiatives amongst the key players of calcium hydroxylapatite (CaHA) fillers is anticipated to propel growth. For instance, in September 2023, CGBio launched its filler range, FACETEM, in Indonesia. Consequently, in October 2023, CGBio signed an export contract worth 100 million USD with HTDK to expand its CaHA filler offerings in Mainland China. Furthermore, in October 2020, AbbVie Inc. acquired Luminera, a company based in Israel with a portfolio and pipeline of dermal fillers.